NCT02799602
- Conditions
- Metastatic Hormone-sensitive Prostate Cancer
- Locations
-
- Chandler, Arizona, United States
- Tucson, Arizona, United States
- Beverly Hills, California, United States
- Duarte, California, United States
Clinical trial condition
Metastatic Hormone-sensitive Prostate Cancer
Explore clinical trials studying Metastatic Hormone-sensitive Prostate Cancer. Study availability and eligibility vary by location and protocol.
20 public trials
6 recruiting studies
Metastatic Hormone-sensitive Prostate Cancer trial results
- Conditions
- Metastatic Hormone-sensitive Prostate Cancer, Parkinson Disease 4, Autosomal Dominant Lewy Body
- Locations
-
- Peking University First Hospital ( Site 0800) Beijing, Beijing Municipality, China
- Beijing Cancer Hospital ( Site 0802) Beijing, Beijing Municipality, China
- Chongqing Cancer Hospital ( Site 0815) Chongqing, Chongqing Municipality, China
- The First Affiliated Hospital of Xiamen University (Site 0816) Xiamen, Fujian, China
NCT05381311
- Conditions
- Genital Diseases, Genital Diseases, Male, Genital Neoplasms, Male, +9 more
- Locations
-
- Duke Clinical Research Institute Durham, North Carolina, United States
NCT06452212
- Conditions
- Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, +7 more
- Locations
-
- KR82001 Seoul, South Korea
NCT06498921
- Conditions
- Metastatic Hormone-sensitive Prostate Cancer
- Locations
-
- Many locations Multiple Locations, Belgium
NCT03532217
- Conditions
- Metastatic Hormone-sensitive Prostate Cancer
- Locations
-
- Washington University School of Medicine St Louis, Missouri, United States
Active, Not Recruiting
An Observational Study to Learn More About Treatment Patterns and Factors Determining the Choice of Treatment in Canadian Men With Metastatic Hormone Sensitive Prostate Cancer in Routine Medical Care
NCT06874114
- Conditions
- Metastatic Hormone-sensitive Prostate Cancer
- Locations
-
- Pentavere Toronto, Ontario, Canada
Active, Not Recruiting
A Study to Learn How Men With Advanced Prostate Cancer Respond to Treatment With Darolutamide and Hormone Therapy, With or Without Chemotherapy, in Real-world Medical Practice
NCT07344779
- Conditions
- Genital Diseases, Genital Diseases, Male, Genital Neoplasms, Male, +8 more
- Locations
-
- Many Locations Multiple Locations, Belgium
- Many Locations Multiple Locations, Finland
- Many Locations Multiple Locations, France
- Many Locations Multiple Locations, Germany
Active, Not Recruiting
A Study for the Participants With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated With Androgen Deprivation Therapy (ADT) Plus Apalutamide or Enzalutamide
NCT05901649
- Conditions
- Metastatic Hormone-sensitive Prostate Cancer
- Locations
-
- Akh Wien Vienna, Austria
- Klinikum Wels Grieskirchen Wels, Austria
- Institut Sainte Catherine Avignon, France
- Institut Bergonie Bordeaux, France
NCT05059236
- Conditions
- Genital Diseases, Genital Diseases, Male, Genital Neoplasms, Male, +8 more
- Locations
-
- Urology Centers of Alabama, PC - Homewood Homewood, Alabama, United States
- Arizona Urology Specialists - Tucson - W Orange Grove Tucson, Arizona, United States
- Tower Urology Los Angeles, California, United States
- UCI Health Center for Urological Care Orange, California, United States